{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BCG-Refractory+Bladder+Cancer&page=2", "query": { "condition": "BCG-Refractory Bladder Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BCG-Refractory+Bladder+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T02:50:07.395Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07322263", "title": "Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Non-Muscle Invasive Bladder Cancer (NMIBC)", "Urothelial Carcinoma", "Carcinoma in Situ (CIS)", "High-Grade Papillary Bladder Tumors", "BCG-Unresponsive Bladder Cancer", "Ta Stage Bladder Cancer", "T1 Stage Bladder Cancer", "BCG-Refractory Bladder Cancer", "High-Risk NMIBC", "Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)" ], "interventions": [ { "name": "Intravesical Gemcitabine and Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael A. O'Donnell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 174, "start_date": "2026-04-10", "completion_date": "2033-01-01", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322263" }, { "nct_id": "NCT03636256", "title": "Evaluation of NanoDoce® in Participants With Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Urothelial Carcinoma", "Urinary Bladder Neoplasm", "Urinary Bladder Cancer", "Urogenital Neoplasms", "Urologic Neoplasms", "Urologic Cancer", "Malignant Tumor of the Urinary Bladder", "Cancer of the Bladder" ], "interventions": [ { "name": "NanoDoce (direct injection)", "type": "DRUG" }, { "name": "NanoDoce (intravesical instillation) - Visit 2 Instillation", "type": "DRUG" }, { "name": "Institutional Standard of Care", "type": "OTHER" }, { "name": "NanoDoce (intravesical instillation) - Induction and Maintenance Instillations", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NanOlogy, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-04-02", "completion_date": "2021-11-02", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Myrtle Beach", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03636256" }, { "nct_id": "NCT05024773", "title": "Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Carcinoma in Situ (CIS)" ], "interventions": [ { "name": "ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fidia Farmaceutici s.p.a.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2022-12-29", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 6, "location_summary": "Gilbert, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05024773" }, { "nct_id": "NCT01118351", "title": "Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Bladder Cancer", "Transitional Cell Carcinoma of the Bladder" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "TdT-mediated dUTP nick end labeling assay", "type": "OTHER" }, { "name": "light microscopy", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2008-10", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2019-05-01", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01118351" }, { "nct_id": "NCT00003129", "title": "Chemotherapy in Treating Patients With Early-Stage Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "valrubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 75, "start_date": "1998-09-01", "completion_date": "2009-05-01", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 10, "location_summary": "Tampa, Florida • Urbana, Illinois • East Orange, New Jersey + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Urbana", "state": "Illinois" }, { "city": "East Orange", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Wynnewood", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003129" }, { "nct_id": "NCT03945162", "title": "Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG" ], "interventions": [ { "name": "Ruvidar® (TLD-1433) bladder infusion and PDT", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Theralase® Technologies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2019-08-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 10, "location_summary": "Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Greenwood", "state": "Indiana" }, { "city": "Syracuse", "state": "New York" }, { "city": "Gahanna", "state": "Ohio" }, { "city": "Bala-Cynwyd", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03945162" }, { "nct_id": "NCT03719300", "title": "Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-muscle Invasive Bladder Cancer (NMIBC)" ], "interventions": [ { "name": "inodiftagene vixteplasmid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anchiano Therapeutics Israel Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2019-03-20", "completion_date": "2019-12-18", "has_results": true, "last_update_posted_date": "2020-08-19", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 48, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719300" }, { "nct_id": "NCT06971614", "title": "A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonmuscle-invasive Bladder Cancer" ], "interventions": [ { "name": "T3011", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImmVira Pharma Co. Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2025-06-09", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2025-07-23", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 2, "location_summary": "Queen Creek, Arizona • Tampa, Florida", "locations": [ { "city": "Queen Creek", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06971614" }, { "nct_id": "NCT06545955", "title": "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ" ], "interventions": [ { "name": "Nadofaragene Firadenovec", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-10-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 38, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 32 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06545955" }, { "nct_id": "NCT04752722", "title": "LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Superficial Bladder Cancer", "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ" ], "interventions": [ { "name": "EG-70 (phase 1)", "type": "DRUG" }, { "name": "EG-70 (phase 2) Master Protocol", "type": "DRUG" }, { "name": "Surfactant Bladder Pre-Rinse and EG-70 (Substudy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "enGene, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2021-04-22", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-06-26T02:50:07.395Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752722" } ] }